the “Corporation”) PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (CDN $0.25 UNITS) INSTRUCTIONS TO SUBSCRIBERSubscription Agreement • September 9th, 2015 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • British Columbia
All Subscribers must sign and deliver to Stellar Biotechnologies, Inc. at its Canadian office, 1868 King George Blvd., South Surrey, British Columbia, V4A 5A1 (Tel: 604-306-8854 / Fax: 604-535-4454):
THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR STATE LAWS, AND MAY NOT BE OFFERED FOR SALE IN THE UNITED STATES OR TO A U.S. PERSON UNLESS EXEMPT THEREUNDER FROM SUCH REGISTATIONPrivate Placement Subscription Agreement • September 9th, 2015 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • British Columbia
The Corporation is offering for sale an aggregate of 11,428,572 Units at a subscription price of US $1.05 per Unit to raise gross proceeds of US $12,000,000. Each Unit is comprised of one common share and one-half of a transferable share purchase warrant. Each whole warrant is exercisable into one additional common share at a price of US $1.35 per common share for a period of thirty-six months from the Closing Date.
Collaboration AgreementCollaboration Agreement • September 9th, 2015 • Stellar Biotechnologies, Inc. • Pharmaceutical preparations • California
This collaboration agreement (the “Agreement”) is entered into and effective as of December 7, 2013 (the “Effective Date”), by and between Stellar Biotechnologies Inc., a California corporation (“SBI”), and Amaran Biotechnology Inc., a Taiwan corporation (“ABI”). SBI and ABI are referred to individually herein from time to time as a “Party,” and collectively as the “Parties.”
